ClinicalTrials.Veeva

Menu
J

Jubilee Clinical Research Inc | Las Vegas, NV

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MK-0616
Amlitelimab
Semaglutide
LPCN 1144
RTA 901
Rocatinlimab
Ruxolitinib
Tolperisone
AXA1125
Lansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 40 total trials

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to lear...

Enrolling
Hyperlipidemia
Drug: Placebo for Rosuvastatin
Drug: Enlicitide

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Active, not recruiting
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo
New

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee oste...

Begins enrollment this month
Knee Osteoarthritis (OA)
Obesity
Drug: NNC0487-0111
Drug: Placebo (matched to NNC0487-0111 )

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux diseas...

Not yet enrolling
GERD (Gastroesophageal Reflux Disease)
Drug: Linaprazan glurate 50 mg Twice Daily (BID)
Drug: Lansoprazole 30 mg Once Daily (QD)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in particip...

Active, not recruiting
MASH
Drug: RO7790121

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL
Locations recently updated

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis
Combination Product: Survodutide
Combination Product: Placebo matching survodutide
Locations recently updated

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Combination Product: Placebo
Combination Product: Survodutide
Locations recently updated

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Topical corticosteroids

The design of the Phase 2 clinical trial includes the following elements:* Multi-center, two-arm, randomized, double-blind, placebo-controlled trial...

Active, not recruiting
Hypertriglyceridemia
Diabetes Mellitus, Type 2
Drug: MN-001 placebo
Drug: MN-001

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed...

Active, not recruiting
Hypercholesterolemia
Drug: Enlicitide Decanoate

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Boehringer Ingelheim logo
Novo Nordisk logo
Sanofi logo
Amgen logo
Gilead Sciences logo
Incyte logo
L
N
Reata Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems